4911 - 4920 of 7616 Results
Title
Year
-
RESTRICTEDTitle: Abstract #81: Improving Neurostimulation Clinical Trial Design with Patient Experience DataJournal Name: Brain StimulationPublisher: Elsevier BVVol: 12Issue #: 2Start Page: e28End Page: e29Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.brs.2018.12.088Citation Count: 0
-
RESTRICTEDTitle: An estimate of the total number of true human miRNAsJournal Name: Nucleic Acids ResearchPublisher: Oxford University Press (OUP)Vol: 47Issue #: 7Start Page: 3353End Page: 3364Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.1093/nar/gkz097Best OA location URL: https://academic.oup.com/nar/article-pdf/47/7/3353/28467549/gkz097.pdfCitation Count: 401
- Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms2019RESTRICTEDTitle: Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptomsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 60Issue #:Start Page: 126End Page: 132Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.parkreldis.2018.09.004Best OA location URL: http://manuscript.elsevier.com/S1353802018303894/pdf/S1353802018303894.pdfCitation Count: 32
- Depressive symptoms may increase the risk of the future development of freezing of gait in patients with Parkinson's disease: Findings from a 5-year prospective study2019RESTRICTEDTitle: Depressive symptoms may increase the risk of the future development of freezing of gait in patients with Parkinson's disease: Findings from a 5-year prospective studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 60Issue #:Start Page: 98End Page: 104Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2018.09.013Citation Count: 31
- Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials2019RESTRICTEDTitle: Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trialsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 60Issue #:Start Page: 118End Page: 125Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2018.09.005Best OA location URL: http://www.prd-journal.com/article/S1353802018303900/pdfCitation Count: 22
- Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders Through Genome-Wide Association Studies2019RESTRICTEDTitle: Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders Through Genome-Wide Association StudiesJournal Name: American Journal of PsychiatryPublisher: American Psychiatric Association PublishingVol: 176Issue #: 3Start Page: 217End Page: 227Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1176/appi.ajp.2018.18070857Best OA location URL: https://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2018.18070857Citation Count: 241
- Memory impairment in Parkinson’s disease: The retrieval versus associative deficit hypothesis revisited and reconciled.2019RESTRICTEDTitle: Memory impairment in Parkinson’s disease: The retrieval versus associative deficit hypothesis revisited and reconciled.Journal Name: NeuropsychologyPublisher: American Psychological Association (APA)Vol: 33Issue #: 3Start Page: 391End Page: 405Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1037/neu0000503Citation Count: 20
- Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial2019RESTRICTEDTitle: Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trialJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 60Issue #:Start Page: 51End Page: 56Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.parkreldis.2018.10.005Best OA location URL: http://manuscript.elsevier.com/S1353802018304310/pdf/S1353802018304310.pdfCitation Count: 15
-
RESTRICTEDTitle: Prioritizing Parkinson’s disease genes using population-scale transcriptomic dataJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 10Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41467-019-08912-9Best OA location URL: https://www.nature.com/articles/s41467-019-08912-9.pdfCitation Count: 129
-
RESTRICTEDTitle: Real-World Experience With VMAT2 InhibitorsJournal Name: Clinical NeuropharmacologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 42Issue #: 2Start Page: 37End Page: 41Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnf.0000000000000326Citation Count: 35